Milestone® Pharmaceuticals Inc. has announced the initiation of the RESET-PSVT registry, a Phase 4, multicenter, prospective observational study aimed at gathering real-world evidence on the use of CARDAMYST™ (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT). Presented at the 2026 Cardiovascular Nursing Symposium, this registry will enroll approximately 450 patients across 20 electrophysiology and cardiology sites, with the goal of starting enrollment by late 2026. This initiative follows the FDA approval of CARDAMYST in December 2025, marking a significant step in the management of PSVT.

The significance of RESET-PSVT lies in its potential to expand the clinical understanding of CARDAMYST’s application beyond controlled trials into everyday clinical practice. By capturing patient-reported outcomes and treatment patterns, the registry aims to elucidate the quality of life, episode burden, and healthcare utilization associated with PSVT management. The primary endpoint focuses on characterizing the usage patterns of CARDAMYST, including frequency and triggers for use, while secondary endpoints will compare outcomes between CARDAMYST and non-CARDAMYST users. This comprehensive data collection is expected to provide valuable insights into the real-world effectiveness and patient experience associated with this novel therapy.

The implications of this registry are profound for the field of cardiovascular research and drug development. RESET-PSVT represents the first of its kind in the PSVT domain, setting a precedent for future studies that prioritize real-world evidence. As the findings become available, they are anticipated to inform clinical guidelines, support healthcare providers in treatment decisions, and enhance the overall understanding of PSVT management, ultimately contributing to improved patient outcomes and healthspan.

Source: globenewswire.com